Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSR4A6)

Drug Name

N-adamantanemethyloxypentyl-1-deoxynojirimycin Drug Info

Synonyms

AMP-Deoxynojirimycin; AMP-DNM; 216758-20-2; CHEMBL574645; N-adamantanemethyloxypentyl-1-deoxynojirimycin; SCHEMBL17132950; SCHEMBL13777990; CTK4E7471; MolPort-044-562-021; ZINC33989734; BDBM50299749; 1613AH; AKOS030538164; RT-011277; N-(Adamantanemethyloxypentyl)-Deoxynojirimycin; J-014228; (2R,3R,4R,5S)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol; 3,4,5-PIPERIDINETRIOL, 2-(HYDROXYMETHYL)-1-[5-(TRICYCLO[3.3.1.13,7]DEC-1-YLMETHOXY)PENTYL]-, (2R,3R,4R,5S)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9822159
TTD Drug ID: DMSR4A6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Lysosomal alpha-glucosidase (GAA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avalglucosidase alfa	DMPW5UF	Pompe disease	5C51.3	Approved	[2]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[3]
BMN-701	DM94Y6O	Pompe disease	5C51.3	Phase 3	[4]
AT845	DMZJIIB	Pompe disease	5C51.3	Phase 2	[5]
SALACINOL	DMVKQT8	N. A.	N. A.	Phase 1/2	[6]
SPK-3006	DMK9DG5	Pompe disease	5C51.3	Phase 1/2	[7]
GZ402666	DMGO6M1	Pompe disease	5C51.3	Phase 1	[8]
5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one	DMAJWLD	Pompe disease	5C51.3	Preclinical	[9]
Alpha-Homonojirimycin	DMT17H0	Discovery agent	N.A.	Investigative	[3]
7-O-b-D-Glucopyranosyl-a-homonojirimycin	DM8IY3D	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysosomal alpha-glucosidase (GAA)	TTLPC70	LYAG_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6600-3.
2	ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health.
3	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
4	Clinical pipeline report, company report or official report of BioMarin Pharma.
5	Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity. EMBO Mol Med. 2022 Jan 11;14(1):e13968.
6	Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4.
7	Clinical pipeline report, company report or official report of Spark Therapeutics
8	ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health.
9	5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2. N.A.. N.A.